Current treatment strategies in autoimmune hemolytic disorders

References

• Petz LD, Garratty G. Immune hemolytic anemias. 2nd edition. Churchill Livingstone; Philadelphia: 2004
   Google Scholar
• Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood 2014;124:2930-6
   PubMed Web of Science ®Google Scholar
• Barcellini W. Pitfalls in the diagnosis of autoimmune haemolytic anaemia. Blood Transfus 2015;13(1):3-5
   PubMed Web of Science ®Google Scholar
• Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory and fatal primary autoimmune hemolytic anemias. Am J Hematol 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serologic findings in autoimmune hemolytic anemia associated with immunoglobulin M warm autoantibodies. Transfusion 2009;49:235-42
   PubMed Web of Science ®Google Scholar
• Visco C, Barcellini W, Maura F, et al. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014;89:1055-62
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol 2015;90:446-60
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006;91:460-6
   PubMed Web of Science ®Google Scholar
• Wang M, Wang W, Abeywardane A, et al. Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King’s College Hospital. Biol Blood Marrow Transplant 2015;21:60-6
   PubMed Web of Science ®Google Scholar
• Aladjidi N, Leverger G, Leblanc T, et al. Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE). New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011;96:655-63
   PubMed Web of Science ®Google Scholar
• Conley CL, Lippman SM, Ness P. Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. JAMA 1980;244:1688-90
   PubMed Web of Science ®Google Scholar
• Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythrocyte response in autoimmune hemolytic anemias: analysis of 109 cases. Blood 1987;69:820-6
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biological studies. Blood 2012;119:3691-7
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol 2013;91:546-51
   PubMed Web of Science ®Google Scholar
• Birgens H, Frederiksen H, Hasselbalch HC, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol 2013;163:393-9
   PubMed Web of Science ®Google Scholar
• Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood 2010;16:1831-8
   Web of Science ®Google Scholar
• Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica 2014;99:1547-54
   PubMed Web of Science ®Google Scholar
• Barros MM, Blajchman MA, Bordin JO. Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment. Transf Med Rev 2010;24:195-210
   PubMed Web of Science ®Google Scholar
• Jaime-Pérez JC, Rodríguez-Martínez M, Gómez-de-León A, et al. Current approaches for the treatment of autoimmune hemolytic anemia. Immunol Ther Exp (Warsz) 2013;61:385-95
   PubMed Web of Science ®Google Scholar
• Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001;43:182-6
   PubMed Web of Science ®Google Scholar
• Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin MIcrobiol Infect 2001;7:657-60
   PubMed Web of Science ®Google Scholar
• Crowther M, Chan YL, Garbett IK, et al. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood 2011;118:4036-40
   PubMed Web of Science ®Google Scholar
• Patel NY, Chilsen AM, Mathiason MA, et al. Outcomes and complications after splenectomy for hematologic disorders. Am J Surg 2012;204(6):1014-19
   PubMed Web of Science ®Google Scholar
• Newland A, Provan D, Myint S. Preventing severe infection after splenectomy. BMJ 2005;331:417-18
   PubMed Web of Science ®Google Scholar
• Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med 2014;37:349-56
   Google Scholar
• Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The post-operative splenic/portal vein thrombosis after splenectomy and its prevention-an unresolved issue. Haematologica 2008;93:1227-32
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973-81
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Ngo M, Iqbal S, et al. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol 2002;118:1166-9
   PubMed Web of Science ®Google Scholar
• Hoffman PC. Immune hemolytic anemia-selected topics. Hematology Am Soc Hematol Educ Program 2009;80-6
   PubMedGoogle Scholar
• Allgood JW, Chaplin HJr. Idiopathic acquired autoimmune hemolytic anemia. a review of forty-seven cases treated from 1955 through 1965. Am J Med 1967;43:254-73
   PubMed Web of Science ®Google Scholar
• Neunert CE, Lim W, Crowther MA, et al. The American society of hematology 2011 evidenced-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207
   PubMed Web of Science ®Google Scholar
• Dierickx D, Verhoef G, Van Hoof A, et al. Rituximab in autoimmune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med 2009;266:484-91
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med 2011;22:220-9
   PubMed Web of Science ®Google Scholar
• Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 2015;14:304-13
   PubMed Web of Science ®Google Scholar
• Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood 2015;125:3223-9
   PubMed Web of Science ®Google Scholar
• Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010;89:1073-80
   PubMed Web of Science ®Google Scholar
• Mahevas M, Michel M, Vingert B, et al. Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Blood 2014;124:21
   Web of Science ®Google Scholar
• Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005;129:534-8
   PubMed Web of Science ®Google Scholar
• O’Connell N, Goodyer M, Gleeson M, et al. Successful treatment with rituximab and mycophenolate mofetil of refractory autoimmune hemolytic anemia post-hematopoietic stem cell transplant for dyskeratosis congenita due to TINF2 mutation. Pediatr Transplant 2014;18(1):E22-4
   PubMed Web of Science ®Google Scholar
• Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol 1993;44:237-42
   PubMed Web of Science ®Google Scholar
• Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol 1990;84:122-9
   PubMed Web of Science ®Google Scholar
• Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol 1993;83:343-5
   PubMed Web of Science ®Google Scholar
• Genty I, Michel M, Hermine O, et al. Caractéristiques des anémies hémolytiques auto-immunes de l’adulte. analyse rétrospective d’une série de 83 patients. Rev Méd Interne 2002;23:901-9
   PubMed Web of Science ®Google Scholar
• Arbach O, Funck R, Seibt F, Salama A. Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia. Transfus Med Hemother 2012;39:221-3
   PubMed Web of Science ®Google Scholar
• Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood 2002;100:704-6
   PubMed Web of Science ®Google Scholar
• Cheung WW, Hwang GY, Tse E, Kwong YL. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica 2006;91(Suppl 5):ECR13
   PubMedGoogle Scholar
• Willis F, Marsh JC, Bevan DH, et al. The effect of treatment with campath-1H in patients with autoimmune cytopenias. Br J Haematol 2001;114:891-8
   PubMed Web of Science ®Google Scholar
• Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007;21:511-14
   PubMed Web of Science ®Google Scholar
• Laurenti L, Tarnani M, Efremov DG, et al. Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 2007;21:1819-21
   PubMed Web of Science ®Google Scholar
• Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep 2009;4:47-53
   PubMedGoogle Scholar
• Quinquenel A, Willekens C, Dupuis J, et al. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). Am J Hematol 2015;90:204-7
   PubMed Web of Science ®Google Scholar
• Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk 2013;13:511-13
   PubMed Web of Science ®Google Scholar
• Smith JW, Weinstein R; for the AABB Hemapheresis Committee. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003;43:820-2
   PubMed Web of Science ®Google Scholar
• Ruivard M, Tournilach O, Montel S, et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case-control study. J Clin Apher 2006;21:202-6
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012;47:770-90
   PubMed Web of Science ®Google Scholar
• Berentsen S. How I manage cold agglutinin disease. Br J Haematol 2011;153:309-17
   PubMed Web of Science ®Google Scholar
• Gertz MA. Management of cold haemolytic syndrome. Br J Haematol 2007;138:422-9
   PubMed Web of Science ®Google Scholar
• Chandesris MO, Schleinitz N, Ferrera V, et al. Cold agglutinins, clinical presentation and significance: retrospective analysis of 58 patients. Rev Med Interne 2004;25:856-65
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjonnfjord GE, Shammas FV, et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol 2000;65:88-90
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood 2013;122:1114-21
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma 2006;47:253-60
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vagan AM, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood 2010;116:3180-4
   PubMed Web of Science ®Google Scholar
• Zoppi M, Oppliger R, Althaus U, Nydegger U. Reduction of plasma cold agglutinin titers by means of plasmapheresis to prepare a patient for coronary bypass surgery. Infusionsther Transfusions Med 1993;20:19-22
   PubMedGoogle Scholar
• Pecsi SA, Almassi GH, Langenstroer P. Deep hypothermic circulatory arrest for a patient with known cold agglutinins. Ann Thorac Surg 2009;88:1326-7
   PubMed Web of Science ®Google Scholar
• Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010;115:915
   PubMed Web of Science ®Google Scholar
• Roth A, Huttmann A, Rother RP, et al. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009;113:3885-6
   PubMed Web of Science ®Google Scholar
• Bommer M, Hochsmann B, Flegel WA, et al. Successful treatment of complement mediated refractory haemolysis associated with cold and warm autoantibodies using eculizumab abstract[abstract 0593]. Haematologica 2009;94(Suppl 2):241-2
   Google Scholar
• Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014;123:4015-22
   PubMed Web of Science ®Google Scholar
• Wouters D, Stephan F, Strengers P, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood 2013;121:1242-4
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 2012;119:6307-16
   PubMed Web of Science ®Google Scholar
• Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 2014;123:2094-101
   PubMed Web of Science ®Google Scholar
• Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis associated with Donath-Landsteiner antibodies. Acta Haematol 1982;68:268-77
   PubMed Web of Science ®Google Scholar
• Gregory GP, Opat S, Quach H, et al. Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Ann Hematol 2011;90:989-90
   PubMed Web of Science ®Google Scholar
• Shulman IA, Branch DR, Nelson JM, et al. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA 1985;253:1746-8
   PubMed Web of Science ®Google Scholar
• Nusbaum NJ, Khosla S. Autoimmune hemolytic anemia with both cold and warm autoantibodies. JAMA 1985;254:1175-6
   PubMed Web of Science ®Google Scholar
• Sokol RJ, Hewitt S, Booker DJ, Morris BM. Patients with red cell autoantibodies: selection of blood for transfusion. Clin Lab Haematol 1988;10:257-64
   PubMedGoogle Scholar
• Yu Y, Sun XL, Ma CY, et al. Serological characteristics and transfusion efficacy evaluation in 61 cases of autoimmune hemolytic anemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2013;21:1275-9
   PubMedGoogle Scholar
• El Kenz H, Efira A, Le PQ, et al. Transfusion support of autoimmune hemolytic anemia: how could the blood group genotyping help? Transl Res 2014;163:36-42
   PubMed Web of Science ®Google Scholar
• Berentsen S, Tjønnfjord GE. Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. Blood Rev 2012;26:107-15
   PubMed Web of Science ®Google Scholar
• Barcellini W, Zaninoni A, Imperiali FG, et al. Anti-erythroblast autoimmunity in early myelodysplastic syndromes. Haematologica 2007;92:19-26
   PubMed Web of Science ®Google Scholar
• Zaninoni A, Imperiali FG, Pomati M, et al. Bone marrow mitogen-stimulated direct antiglobulin test in a case of erythroblastic synartesis. Clin Lab 2010;56:459-62
   PubMed Web of Science ®Google Scholar